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Introduction {#sec1}
============

Induced pluripotent stem (iPS) cells, generated by introducing defined factors to reprogram terminally differentiated somatic cells, offer enormous potential for the development of autologous or customized cellular therapies to treat or correct many inherited and acquired diseases ([@bib19], [@bib21]). Complications associated with immunorejection can be avoided through the generation and subsequent disease correction of patient-specific iPS cells, which can be differentiated into relevant cell types for the repopulation and regeneration of a defective tissue or organ. Gene targeting by homologous recombination is the ideal approach for the correction of genetic defects as it enables replacement of the defective allele with a normal functional one without disturbing the remaining genome. The generation of a genetically modified iPS cell line typically involved multiple procedures that required the cells to be in culture for an extensive period, drug selection, and several clonal events ([@bib6], [@bib9], [@bib12], [@bib23]). In the first step, somatic cells are reprogrammed, and several clones are expanded and characterized. Gene targeting constructs are then introduced, and cells are usually subjected to drug selection to isolate and identify correctly modified iPS cell colonies. Once successfully targeted clones are identified, it is preferable to excise the drug selectable marker, commonly flanked by loxP or FRT sites. Taken together, the multiple steps required for the generation of genetically modified iPS cell lines typically require cells to be in culture for several months, which is not compatible for patients for whom urgent medical intervention is imperative. Furthermore, there is evidence to suggest that increased culture times are associated with undesirable changes in genomic integrity, such as duplications of oncogenic genes ([@bib10]) and other karyotypic abnormalities ([@bib2]). Here we report that reprogramming and gene targeting can be performed together in a one-step procedure that requires only a single electroporation. Multiple gene-targeted iPS cell clones can be generated from patient cells in as little as 2 weeks, requiring only a single clonal event. The procedure also does not require the use of drug selection and permits the generation of clones that contain "seamless" single base-pair changes, without leaving residual loxP or FRT sites in the host genome.

Results {#sec2}
=======

We used an enhanced episomal-based reprogramming system to generate iPS cell lines that would eventually be free of vector sequences. In addition to the seven factors (*OCT4*, *SOX2*, *NANOG*, *c-MYC*, *KLF4*, *LIN28*, and the SV40 Large T-Antigen) encoded by the three oriP-based vectors previously reported to induce pluripotency ([@bib22]), we also forced expression of the micro RNA (miR) 302/367 cluster, which is known to facilitate reprogramming and maintenance of pluripotency ([@bib11], [@bib15]). The inclusion of an additional episomal vector encoding miR 302/367 resulted in a substantial increase (more than 100-fold) in the total number of iPS cell colonies in human fibroblasts ([Figure 1](#fig1){ref-type="fig"}). This plasmid was included in all subsequent reprogramming experiments and was necessary to obtain sufficient iPS cell colony numbers when combining gene targeting and reprogramming in a single step.

In our initial attempts at simultaneous reprogramming and gene targeting of somatic cells, we chose to target the *DNMT3B* gene with an EGFP reporter, since *DNMT3B* is highly expressed in pluripotent cells and quickly downregulated following differentiation, allowing targeted iPS cell colonies to be easily identified by fluorescent microscopy. To facilitate homologous recombination at the *DNMT3B* locus, we used in vitro transcribed mRNA encoding the Cas9 protein derived from *N. meningitides* ([@bib7]), a plasmid encoding a *DNMT3B*-specific short-guide (sg)RNA and a donor template encoding an EGFP reporter and puromycin resistance gene flanked by 1-kb homology arms specific to sequences upstream and downstream of the *DNMT3B* start codon ([Figure 2](#fig2){ref-type="fig"}A). We first evaluated targeting of *DNMT3B* using this system in the embryonic stem cell line H9 and routinely obtained a gene-targeting efficiency of 0.5%--0.9% ([Figure 2](#fig2){ref-type="fig"}B). We next co-transfected the reprogramming plasmids along with the *DNMT3B*-specific gene-targeting factors into a fibroblast line derived from a patient with autosomal dominant retinitis pigmentosa. Although iPS cell colonies first emerged as early as 10 days following transfection, we observed the vast majority emerge between 2 and 3 weeks postelectroporation, at which point the culture was routinely analyzed by fluorescent microscopy. Of three independent experiments we identified 8, 13, and 44 iPS cell colonies that stably expressed the EGFP reporter, indicative of a successful gene-targeting event at the *DNMT3B* locus ([Figure 2](#fig2){ref-type="fig"}C). We obtained a large number of iPS cell colonies (\>1,000) from each of these experiments, making it difficult to accurately assess gene-targeting efficiency. Thus, to estimate targeting efficiency in the pool of iPS cells, we passaged cells from a single representative experiment approximately 3 weeks post-transfection using EDTA to selectively remove iPS cells from the residual fibroblasts before re-plating. As measured by the number of EGFP-expressing cells, targeting efficiency was approximately 3% and 5% following flow cytometric analysis of the total cell population after three and five passages, respectively ([Figure 2](#fig2){ref-type="fig"}D). An increase in the number of EGFP-expressing cells is most likely due to a further loss of the residual parental fibroblast population, and we did not observe any further increase in the number of EGFP-expressing cells after five passages. Using the reprogramming experiments that were not passaged, we randomly selected and expanded six EGFP-expressing and six EGFP-non-expressing colonies for further analysis. Gene targeting of the *DNMT3B* locus was confirmed in all six EGFP-expressing clones by PCR using primers that flank the recombination junction site, but not in any of the EGFP-non-expressing clones ([Figure 2](#fig2){ref-type="fig"}E). Flow cytometry analysis also revealed a uniform level of EGFP expression in \> 95% of the cell population with similar fluorescence intensities observed in all six clones ([Figure 2](#fig2){ref-type="fig"}F). Although targeting of *DNMT3B* in H9 cells with the same donor template routinely yielded numerous puromycin-resistant colonies, confirming functionality of the phosphoglycerate kinase (PGK) promoter in pluripotent stem cells, EGFP-expressing iPS cell lines generated by simultaneous reprogramming and targeting of *DNMT3B* exhibited puromycin sensitivity. This suggests the PGK promoter was transcriptionally silenced during the reprogramming process, making drug selection of simultaneously reprogrammed and gene-targeted clones infeasible. Conversely, when we used a one-step procedure to generate iPS cell lines with an EGFP reporter fused to the *OCT4* coding region using the Cas9/CRISPR system described previously ([@bib7]) ([Figure S1](#mmc1){ref-type="supplementary-material"}), these clones did exhibit resistance to puromycin in the culture media. In this case the puromycin resistance gene is fused to the EGFP reporter via a 2A sequence and is thereby driven from the endogenous *OCT4* regulatory region rather than the minimal and non-specific PGK promoter.

We have also successfully used our one-step protocol to simultaneously reprogram and genetically correct the disease-causing mutation in the patient fibroblasts, an autosomal dominant C \> T transition in exon 42 of the *PRPF8* gene. This was achieved using a plasmid encoding the Cas9 protein from *S. pyogenes* ([@bib14]), a plasmid encoding a *PRPF8*-specific sgRNA that binds 33 bp upstream of the disease-causing mutation, and a 184-bp single-stranded oligodeoxynucleotide (ssODN) ([Figure 3](#fig3){ref-type="fig"}A). The ssODN was engineered to contain four synonymous mutations to minimize the possibility of Cas9 protein re-cutting following homologous recombination and to aid in the identification of clones that had undergone a gene-targeting event ([Figure 3](#fig3){ref-type="fig"}A). Approximately 3 weeks post-transfection, we randomly isolated and expanded a total of 72 iPS cell colonies for further analysis. A PCR product encoding the region of interest was amplified from the genomic DNA of all 72 clones using primers flanking the target site, which was subsequently analyzed by Sanger sequencing. Cas9-induced modification of one or both *PRPF8* alleles was observed in 22 (31%) of the clones analyzed, most commonly detected as a nonhomologous end joining (NHEJ) event within the intended cut site. Homologous recombination at the target site could be detected in 6 (8%) clones, as evidenced by the loss of the disease-causing mutation or the presence of one or more synonymous mutations carried by the corrective ssODN ([Table 1](#tbl1){ref-type="table"}). Genetic correction of the autosomal dominant patient-specific mutation was observed in 2 clones, while targeting of the wild-type allele was observed in 4 clones. We were unable to determine which allele had undergone gene targeting in 1 clone (P.57) due to a 151-bp deletion spanning the site of the mutation. Surprisingly, 1 clone (P.50) appeared to have undergone bi-allelic homologous recombination, as evidenced by correction of the patient-specific mutation and the presence of ssODN-specific synonymous mutations on both alleles ([Figures 3](#fig3){ref-type="fig"}B and 3C). However, this clone also contained a 1-bp deletion approximately 50 bp upstream of the intended site of the Cas9-induced double-stranded break. We hypothesize that this is most likely due to homologous recombination with an incorrectly synthesized ssODN rather than an additional mutation caused by NHEJ, which normally occurs at the site of the double-stranded break.

Next we attempted to correct the disease-causing mutation in a fibroblast line isolated from an infant with severe combined immunodeficiency (SCID), caused by mutations in the gene encoding adenosine deaminase (ADA). SCID patients could particularly benefit from a one-step protocol that facilitates the expedited generation of gene-corrected iPS cells because without early intervention, such as a bone marrow transplant, patients typically die within the first 1 to 2 years of life. We first attempted to simultaneously reprogram and target *DNMT3B* in ADA-SCID fibroblasts and identified one EGFP-expressing colony (0.9%) out of a total of 108 iPS cell colonies ([Figure S2](#mmc1){ref-type="supplementary-material"}). PCR analysis confirmed targeting of the *DNMT3B* locus (see [Figure 2](#fig2){ref-type="fig"}E). We next attempted to simultaneously reprogram and correct one of the disease-causing mutations in the ADA-SCID fibroblasts using our one-step protocol. The fibroblasts were derived from a patient who is a compound heterozygote: one allele has a C \> T transition in exon 11 of the *ADA* gene (1,081C \> T), and the second allele has an A \> G transition in the 3-prime splice site of intron 3, resulting in a deletion of exon 4 from mature mRNA. We chose to correct the C \> T transition in exon 11 using an sgRNA specific to the mutant, but not wild-type, exon 11 sequence of the *ADA* gene ([Figure 4](#fig4){ref-type="fig"}A). We hypothesized that this would minimize Cas9 cutting in both alleles, as seen in the majority of the *PRPF8* gene-targeted iPS cell lines, where only 1 out of the 6 clones did not have a second allele modified, either by NHEJ or a second homologous recombination event. To facilitate gene correction we used a 175-bp single-stranded corrective ssODN, which was engineered to contain a single synonymous mutation within the Cas9 target site ([Figure 4](#fig4){ref-type="fig"}A). A total of 55 colonies were expanded and screened, with Cas9-induced modification of *ADA* exon 11 observed in 20 (36%) clones, as determined by Sanger sequencing of a 1.4-kb PCR product amplified from genomic DNA using primers flanking the target site. Gene targeting was detected in 3 (5%) clones, as evidenced by the loss of the disease-causing mutation and the presence of the synonymous mutation carried by the corrective ssODN. Genetic correction of the patient-specific mutation in exon 11 was observed in all three clones, without modification of the second allele, indicating that Cas9 preferentially favored the mutant exon 11 sequence (over wild-type). This was also evident upon analysis of the uncorrected clones that had undergone NHEJ at the target site. Interestingly, in one gene-corrected iPS cell line, we also detected a G \> A transition approximately 35 bp downstream of the intended site of the Cas9-induced double-stranded break ([Figure 4](#fig4){ref-type="fig"}B). Again, due to its location relative to the Cas9 target site, we hypothesize that this is most likely the result of homologous recombination with an incorrectly synthesized ssODN. Expression of corrected *ADA* mRNA was also confirmed in all three gene-corrected iPS cell lines following total RNA extraction and RT-PCR to amplify the complete *ADA* transcript, which was then sequenced ([Figure 4](#fig4){ref-type="fig"}C). The two gene-corrected lines that did not carry the additional G \> A transition were characterized further by teratoma formation, G-banding, and PCR analysis to detect residual reprogramming plasmids. Both clones formed teratomas comprising all three primary germ layers following injection into immunocompromised mice ([Figure S3](#mmc1){ref-type="supplementary-material"}A), exhibited normal karyotypes ([Figure S3](#mmc1){ref-type="supplementary-material"}B), and were found to be free of residual plasmid sequences ([Figure S3](#mmc1){ref-type="supplementary-material"}C).

To further investigate the possibility that incorrectly synthesized oligonucleotides may introduce additional mutations following homologous recombination with the host genome, we performed sequencing analysis of the *ADA*- and *PRPF8*-specific ssODNs used for gene repair in the experiments described previously. ssODNs were PCR amplified using primers that bind the 5′ and 3′ ends and inserted into a plasmid vector. We then analyzed the oligonucleotide-specific sequences in individual clones by Sanger sequencing. In a control experiment, to estimate polymerase error rate, *PRPF8*-specific ssODN sequence from one representative clone was PCR amplified, re-cloned and subsequently analyzed by Sanger sequencing. No mutations were detected in any of the 30 clones analyzed from the control experiment. In contrast, mutations were detected in approximately 28% (9/32) and 29% (10/34) of clones harboring the *PRPF8* and *ADA* ssODN sequences, respectively ([Figure 5](#fig5){ref-type="fig"}). Although single nucleotide deletions were the most common type of mutation observed, single base insertions, single base substitutions, and deletions up to three bases in size were also detected ([Table S1](#mmc1){ref-type="supplementary-material"}). Furthermore, mutations were observed throughout the ssODN and did not appear to exhibit any significant positional bias. Interestingly, a mutation within one *ADA*-specific ssODN sequence was also detected at the same location as that observed in the *ADA* gene-corrected iPS line with the additional G \> A transition. Since the ssODNs used in our study were \> 150 bases in size and purified by standard desalting, perhaps the incidence of additional mutations following gene repair could be reduced by using ssODNs that are smaller in length or purified by PAGE or high-pressure liquid chromatography (HPLC) following synthesis.

Discussion {#sec3}
==========

We have demonstrated the feasibility of performing reprogramming and gene correction together in a simple one-step procedure that enables the generation of multiple gene-corrected and uncorrected iPS cell lines in as little as 2 weeks, requiring considerably less time and resources compared to conventional multi-step protocols that can take several months to complete. In a therapeutic context this should facilitate transplantation medicine by making gene-corrected cells available to patients in a more timely manner, while potentially minimizing the risks associated with extended cell culture, drug selection, and multiple clonal events. In addition, we anticipate that comparisons between corrected and matched uncorrected control iPS cell lines generated from a single experiment will also be extremely useful for disease modeling and understanding the underlying molecular mechanisms governing disease, because any observed differences between corrected and uncorrected cells can be attributed to the patient-specific mutation rather than differences in genetic background.

However, it is important to note that a number of studies have demonstrated that iPS cell lines derived from skin biopsies typically harbor a unique subset of de novo genetic abnormalities, either in the form of copy-number variation or single base-pair changes ([@bib1], [@bib4]) and that iPS cell lines generated from the same parental line can vary significantly with respect to whole-genome gene expression in the differentiated state ([@bib17]). Nonetheless, it is reasonable to expect that the confounding effects arising from the variations that exist across different iPS cell clones may be minimized by comparing multiple gene-corrected or gene-targeted clones with multiple uncorrected clones. In this regard a consistent difference that is observed exclusively in the corrected versus uncorrected lines can most likely be attributed to the patient-specific mutation rather than variations that may exist from one clone to the next. In the current study we routinely observed targeting efficiencies of \> 5%, enabling the generation of multiple gene-targeted and "matched" uncorrected clones from a single experiment.

The relatively high gene-targeting frequencies obtained using our one-step protocol may in part be attributed to the possibility that the iPS cell colonies themselves act as a form of selection. This is based on the assumption than an iPS cell colony that has taken up the plasmids required for reprogramming will have also taken up the DNA constructs required for gene targeting. Following simultaneous reprogramming and targeting of the *DNMT3B* locus in the fibroblast line derived from a patient with retinitis pigmentosa, the estimated targeting efficiency in the total iPS cell population was approximately 5%, more than 5-fold higher than that observed in the embryonic stem cell line H9. With respect to the *ADA* and *PRPF8* gene correction experiments, we obtained targeting efficiencies of 5% and 8%, respectively. This is notably higher than the frequencies of gene targeting that have previously been reported in pluripotent stem cells using ssODNs, without the aid of drug selection, where correctly targeted cells typically comprise less than 1% of the total population ([@bib18], [@bib20]). Another notable advantage of our one-step protocol over conventional approaches is that it does not require additional steps for the clonal isolation of iPS cells. In the absence of selection, this is most often performed using fluorescently activated cell sorting or limiting cell dilution to expand a clonal population from a single iPS cell, which is inefficient and cumbersome because human pluripotent stem cells exhibit poor survivability in the absence of appropriate cell-to-cell contacts.

Although bi-allelic Cas9-induced modification was a common outcome in the iPS cell lines generated in this study, we show that this can be minimized by designing sgRNAs that specifically target patient-specific mutations. This approach is feasible for patients with autosomal dominant and compound heterozygous mutations, but not for mutations that are autosomal recessive. However, since autosomal recessive diseases normally require only a single functional allele, bi-allelic modification resulting in correction of one allele and mutagenic NHEJ in the other, is less of a concern. It will also be important to evaluate the use of Cas9 variants that have improved DNA cleavage specificity in the protocol described here. Use of the paired nickase (Cas9-D10A) ([@bib13], [@bib16]) and dCas9-Fok1 fusions (fCas9) ([@bib5]), for example, should minimize the potential of off-target effects that are largely associated with the wild-type form of the Cas9 protein. Keeping background damage to a minimum will be essential not only for retaining the downstream therapeutic potential of the cells but also for an accurate recapitulation of the disease and corrected (wild-type) phenotype, which will be important for disease modeling and drug discovery purposes. Finally, there is also significant value in adapting our protocol to permit the generation of gene-corrected iPS cell lines from alternative cell sources such as blood, which involve less invasive procedures and may harbor fewer somatic mutations compared with fibroblasts derived from skin biopsies. Since expansion of fibroblasts from an initial skin biopsy can take several weeks, the ability to simultaneously reprogram and genetically repair cells isolated from blood draws will also serve to expedite the process of generating gene-corrected iPS cell lines even further.

Experimental Procedures {#sec4}
=======================

Plasmid DNA and mRNA {#sec4.1}
--------------------

The episomal vectors (pEP4EO2SEN2L, pEP4EO2SET2K, and pEP4EO2SEM2K) carrying seven factors for reprogramming have been described previously ([@bib22]). An additional plasmid carrying the miR 302/367 cluster was generated by PCR---amplifying an approximately 1.2-kb fragment from genomic DNA (extracted from human embryonic stem cell line H1) and cloned into the pSimpleII plasmid (an OriP-containing plasmid) under the control of the elongation factor-1α promoter. The plasmids used for targeting OCT4 have been previously described ([@bib7]). The plasmid hCas9 was a gift from George Church (Addgene plasmid \#41815). All sgRNA targeting the *DNMT3B*, *PRPF8*, or *ADA* genes were driven from a U6 promoter cloned into pstBlue-1 (Novagen). The *DNMT3B* targeting vector was generated by inserting a DNA cassette encoding an EGFP reporter, PGK-promoter-driven puromycin gene, and kanamycin gene flanked by FRT sites into a bacterial artificial chromosome (BAC) clone containing the complete *DNMT3B* coding region (CTD-2608L15) using the Red-ET recombination system (Genebridges). The kanamycin resistance gene was subsequently removed from the gene-targeting vector with Flpe-recombinase (Genebridges). All plasmids were prepared by cesium chloride gradient extraction. In vitro transcribed mRNA encoding Cas9 and EBNA1 was generated using the SP6 mMessage mMachine kit (Life Technologies). ssODNs (Ultramers) were purchased from Integrated DNA Technologies.

Fibroblast Culture {#sec4.2}
------------------

Fibroblasts derived from a patient with retinitis pigmentosa were obtained from the Peirce Lab, Penn State University, and ADA-SCID fibroblasts were obtained from Coriell Laboratories (ID no. GM02824). Fibroblasts were cultured in DMEM (Invitrogen) supplemented with 15% fetal bovine serum (FBS) (HyClone) at 37°C, 5% CO~2~, and 5% O~2~.

Flow Cytometry {#sec4.3}
--------------

Cells were analyzed for EGFP expression by flow cytometry using a FACSCanto II flow cytometer (BD Biosciences). Data acquisition and analysis were performed using FACsDiva software version 6.1.3 (BD Biosciences) and FlowJo (Tree Star) software version 9.5.1. Gating was performed on live cells based on forward and side scatter analysis.

Reprogramming/Gene Correction {#sec4.4}
-----------------------------

Fibroblasts were harvested 2 days after passaging and resuspended in OptiMEM (Life Technologies) at a final concentration of 4--6 × 10^6^ cells/ml. 500 μl of the cell suspension was added to a 0.4-cm cuvette containing the reprogramming and gene-targeting DNA constructs and electroporated (220 V, 1,000 μF) using the Gene Pulser II (BioRad). See [Table S2](#mmc1){ref-type="supplementary-material"} for DNA concentrations used for each experiment. In vitro transcribed mRNA encoding a truncated version of the EBNA1 protein was also included to enhance nuclear uptake of the oriP-containing reprogramming vectors ([@bib3], [@bib8]). Following electroporation, cells were plated on a single 10-cm Matrigel-coated (Corning) plate and maintained in fibroblast media until 4 days post-transfection, and then they were switched to E7 medium (E8 medium without transforming growth factor β) with 100 μM sodium butyrate and changed every other day as described previously ([@bib3]). Sodium butyrate was removed from the media after the appearance of the first iPS cell colonies at around day 10. After isolation, iPS cells were maintained and expanded in E8 medium with daily media changes and passaged every 3--4 days with EDTA in 1× PBS as previously described ([@bib3]).

PCR, RT-PCR, and Sanger Sequencing {#sec4.5}
----------------------------------

Total genomic DNA was extracted by using the DNeasy Blood and Tissue Kit (QIAGEN). Total RNA was extracted by using the RNeasy Plus Mini Kit (QIAGEN). cDNA was synthesized using SuperScript III (Life Technologies) according to the manufacturer's protocol. PCR was performed by using GoTaq Green PCR Mastermix (Promega). Prior to sequencing, PCR products were treated with rAPid Alkaline Phosphatase (Roche Life Science) and Endonuclease I (NEB) for 30 min at 37°C followed by heat inactivation at 80°C for 15 min. Sequencing reactions were performed using BigDye Terminator v3.1 (Life Technologies). Reactions were then purified and sequenced by the Genome Center, University of Wisconsin. For sequencing analysis of single alleles, PCR products amplified from genomic DNA extracted from each of the *PRPF8* gene-corrected clones were cloned into the pUC19 vector (Life Technologies). Plasmid DNA was extracted from 12 randomly selected colonies for each of the 6 cloned PCR products and sequenced as described above.

Oligonucleotide Sequences {#sec4.6}
-------------------------

For lists of primers used in this study for PCR amplification and generation of sgRNA plasmids, see [Table S3](#mmc1){ref-type="supplementary-material"}.
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![Episomal Reprogramming System Is Enhanced with Inclusion of Plasmid Encoding the miR302/367 Cluster\
Reprogramming experiments were performed with and without inclusion of the miR302/367 expression plasmid using a normal male fibroblast line. Data represent an average of three independent experiments ± SD.](gr1){#fig1}

![Gene Targeting of the *DNMT3B* Locus\
(A) Schematic diagram of the *DNMT3B* locus and the donor template used for gene targeting. pA, polyA signal; Ex, exon.\
(B) Flow cytometric analysis of H9 cells 3 days following the transfection of *DNMT3B*-specific donor template, mRNA encoding Cas9 protein, and plasmid carrying DNMT3B-specific sgRNA.\
(C) Representative phase contrast and fluorescent images of an iPS cell colony generated after simultaneous reprogramming and gene targeting of *DNMT3B* in fibroblasts derived from a patient with retinitis pigmentosa, acquired 2.5 weeks post-electroporation.\
(D) Flow cytometric analysis of the total cell population after EDTA passaging, initiated approximately 3 weeks post-electroporation. Analysis was performed after three and five passages.\
(E) PCR analysis across recombination junction to confirm gene targeting of *DNMT3B*, using primers specific to sequence upstream of 3′ homology arm and EGFP. Analysis was performed on 6 EGFP-expressing iPS cell clones (lanes G1--G6) and 6 EGFP-non-expressing iPS cell clones (lanes C1--C6). An H9-derived DNMT3B-EGFP knockin and BAC carrying EGFP inserted at *DNMT3B* start codon (used to generate donor template) were included as positive controls.\
(F) Flow cytometric analysis of EGFP-expressing iPS cell lines generated after simultaneous reprogramming and gene targeting of the *DNMT3B* locus.](gr2){#fig2}

![Simultaneous Reprogramming and Genetic Correction of the *PRPF8* Gene in Fibroblasts from a Patient with Retinitis Pigmentosa\
(A) Schematic diagram of the *PRPF8* gene, with mutation in exon 42. The Cas9 target site (red), the patient-specific mutation (blue), and antisense single-stranded DNA template used for gene repair are shown.\
(B) Sequencing analysis of exon 42 of the *PRPF8* gene in the genomic DNA from uncorrected patient-specific iPS cells. Both wild-type and mutant alleles are shown.\
(C) Sequencing analysis of genomic DNA from a single iPS cell clone following successful simultaneous reprogramming and genetic correction of patient-specific fibroblasts. Both alleles appear to have undergone homologous recombination with the corrective ssODN as evidenced by the presence of the ssODN-specific synonymous mutations (SM 1-4) on both alleles. One allele also has a single base-pair deletion, which is most likely caused by an ssODN that was incorrectly synthesized. The location of the patient-specific mutation and synonymous mutations introduced by the repair ssODN are marked by black boxes.](gr3){#fig3}

![Simultaneous Reprogramming and Genetic Correction of ADA-SCID Fibroblasts\
(A) Schematic diagram of the *ADA* gene, with mutation in exon 11. The Cas9 target site (red), the patient-specific mutation (blue), and antisense single-stranded DNA template used for gene repair are shown.\
(B) Sequencing analysis of exon 11 of the *ADA* gene in the genomic DNA of an uncorrected and two gene-corrected iPS cell lines derived from ADA-SCID fibroblasts. One of the gene-corrected lines (clone Bb) was also found to carry a G \> A transition approximately 35 bp downstream of the intended DNA double-stranded break, and most likely introduced by an incorrectly synthesized ssODN.\
(C) Sequencing analysis of the *ADA* transcript amplified from the cDNA of an uncorrected and two gene-corrected iPS cell lines. The location of the patient-specific mutation, synonymous mutation, and G \> A transition introduced by the repair ssODN are marked by black boxes.](gr4){#fig4}

![Sequencing Analysis of Oligonucleotides Used in Gene Repair Experiments\
The number of plasmid clones (expressed as percentage of total clones analyzed) carrying oligonucleotide sequence with at least one mutational event is shown. As a control, the *PRPF8*-specific oligonucleotide sequence from a single plasmid clone was PCR-amplified and re-cloned to assess polymerase error rate.](gr5){#fig5}

###### 

Analysis of Gene-Targeted iPS Cell Clones Derived from Patient with Retinitis Pigmentosa

  Clone   Modification Observed at *PRPF8* Target Site (Exon 42)
  ------- -------------------------------------------------------------------------------------------------------------------------------------------------------------
  P.16    no correction of mutation but presence of SM1 and SM2 on mutant allele; wild-type allele unmodified
  P.50    one allele contains SMs 1--3; other allele contains SMs 1--4 and 1-bp deletion ≈30 bp upstream of Cas9 target site
  P.57    one allele contains SMs 1--3; other allele contains 151-bp deletion (spanning 124 bp downstream and 7 bp upstream of Cas9 target site) and 105-bp insertion
  P.71    correction of mutant allele, but no SMs present; wild-type allele has a 2-bp insertion within Cas9 target site
  P.72    wild-type allele contains SMs 1--4; mutant allele has 1-bp deletion
  P.73    wild-type allele contains SMs 1--3; mutant allele has 2-bp deletion within Cas9 target site

SM, synonymous mutation.
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